Abstract
The control of gene expression is critical for metabolic engineering. The multi-copy plasmids has been widely used for high-level expression of genes. However, plasmid-based expression systems are liable to genetic instability and require a selective pressure to assure plasmid stability. In this study, we first constructed a lycopene producer Escherichia coli through promoter engineering. Saccharomyces cerevisiae mevalonate (MEV) pathway was also optimized to balance expression of the top and bottom MEV pathway by using the different strength promoters. The chromosomal heterologous expression of the optimized S. cerevisiae MEV pathway can further improved lycopene production. The final engineered strain, E. coli LYCOP 20, produced lycopene of 529.45 mg/L and 20.25 mg per gram of dry cell weight in the fed-batch culture. The engineered strain does not have a plasmid or antibiotic marker. This strategy used in this study can be applied in pathway engineering of E. coli and other bacteria.
Keywords: Escherichia coli, lycopene, promoter engineering.
Current Pharmaceutical Biotechnology
Title:Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering
Volume: 16 Issue: 12
Author(s): Hong-Jie Shen, Jin-Jing Hu, Xi-Ran Li and Jian-Zhong Liu
Affiliation:
Keywords: Escherichia coli, lycopene, promoter engineering.
Abstract: The control of gene expression is critical for metabolic engineering. The multi-copy plasmids has been widely used for high-level expression of genes. However, plasmid-based expression systems are liable to genetic instability and require a selective pressure to assure plasmid stability. In this study, we first constructed a lycopene producer Escherichia coli through promoter engineering. Saccharomyces cerevisiae mevalonate (MEV) pathway was also optimized to balance expression of the top and bottom MEV pathway by using the different strength promoters. The chromosomal heterologous expression of the optimized S. cerevisiae MEV pathway can further improved lycopene production. The final engineered strain, E. coli LYCOP 20, produced lycopene of 529.45 mg/L and 20.25 mg per gram of dry cell weight in the fed-batch culture. The engineered strain does not have a plasmid or antibiotic marker. This strategy used in this study can be applied in pathway engineering of E. coli and other bacteria.
Export Options
About this article
Cite this article as:
Shen Hong-Jie, Hu Jin-Jing, Li Xi-Ran and Liu Jian-Zhong, Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering, Current Pharmaceutical Biotechnology 2015; 16 (12) . https://dx.doi.org/10.2174/1389201016666150731110536
DOI https://dx.doi.org/10.2174/1389201016666150731110536 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer
Target by Manumycin-related Natural Products
Current Medicinal Chemistry Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma
Current Molecular Pharmacology Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Selection of Single Chain Antibody Fragments for Targeting Prostate Specific Membrane Antigen: A Comparison Between Cell-based and Antigen-based Approach
Protein & Peptide Letters Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Inhibition of Fatty Acid Synthase by Polyphenols
Current Medicinal Chemistry Editorial [Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement. PART I. (Executive Editors: Calogero Caruso Thea Magrone and Emilio Jirilllo)]
Current Pharmaceutical Design DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Neopterin as a Marker for Immune System Activation
Current Drug Metabolism